HALO 📈 Halozyme Therapeutics - Overview

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company, focusing on the research, development, and commercialization of its proprietary enzymes and devices globally, with a presence in the United States, Switzerland, Belgium, Japan, and other international markets. The company's core technology revolves around the patented recombinant human hyaluronidase enzyme, known as rHuPH20, which plays a crucial role in facilitating the delivery of injectable biologics. This includes monoclonal antibodies, other therapeutic molecules, small molecules, and fluids, thereby enhancing their absorption and dispersion in the body.

The application of rHuPH20 is diverse, with products such as Hylenex recombinant, designed to facilitate subcutaneous fluid administration. This is particularly useful for achieving hydration, enhancing the dispersion and absorption of other injected drugs, and improving the resorption of radiopaque agents in subcutaneous urography. Additionally, the company is involved in the development and commercialization of treatments for various diseases, including HIV, through products like rilpivirine and cabotegravir, and for multiple sclerosis, with ocrelizumab. It also offers XYOSTED, an injection for subcutaneous administration of testosterone replacement therapy, and ATRS-1902, a proprietary drug-device combination product.

Halozyme Therapeutics, Inc. has a broad portfolio that includes products for the treatment of breast cancer, such as Herceptin and Herceptin Hylecta, and Mabthera SC for chronic lymphocytic leukemia. It also provides HYQVIA for primary immunodeficiency disorders and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. The company's offerings extend to treatments for allergic reactions with Epinephrine Injection, and for solid tumors with nivolumab+relatlimab and ANTI-TIM3. Furthermore, it includes ARGX-117 for multifocal motor neuropathy, atezolizumab, nivolumab, afgartigimod, teriparatide injections, and OTREXUP, a subcutaneous methotrexate injection for severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as for children with active polyarticular juvenile idiopathic arthritis.

Established in 1998, Halozyme Therapeutics, Inc. is headquartered in San Diego, California, and is publicly traded on the NASDAQ stock exchange under the ticker symbol HALO. With a strong focus on biotechnology, the company continues to innovate and expand its portfolio of enzyme-based therapies and drug delivery systems, aiming to improve patient outcomes across a range of diseases. The company's commitment to research and development is reflected in its diverse product pipeline and collaborations with other pharmaceutical companies to enhance drug delivery and efficacy.